<code id='138AC8BC98'></code><style id='138AC8BC98'></style>
    • <acronym id='138AC8BC98'></acronym>
      <center id='138AC8BC98'><center id='138AC8BC98'><tfoot id='138AC8BC98'></tfoot></center><abbr id='138AC8BC98'><dir id='138AC8BC98'><tfoot id='138AC8BC98'></tfoot><noframes id='138AC8BC98'>

    • <optgroup id='138AC8BC98'><strike id='138AC8BC98'><sup id='138AC8BC98'></sup></strike><code id='138AC8BC98'></code></optgroup>
        1. <b id='138AC8BC98'><label id='138AC8BC98'><select id='138AC8BC98'><dt id='138AC8BC98'><span id='138AC8BC98'></span></dt></select></label></b><u id='138AC8BC98'></u>
          <i id='138AC8BC98'><strike id='138AC8BC98'><tt id='138AC8BC98'><pre id='138AC8BC98'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:leisure time    - browse:9
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia